



Contact:

David Waldman or Justyna Gudaszewska

Crescendo Communications Europe Sp. z o.o

Email: mmd@crescendo-ir.com

Tel: (+48) 693 354 580

Following Successful FDA Marketing Clearance of the CompuFlo™ Epidural Instrument, Milestone Medical Appoints Daniel Goldberger as CEO to Lead Transition to a Commercially Focused Global Medical Device Company

LIVINGSTON, NJ, July 12, 2017 -- Milestone Medical Inc. (WAR: MMD), today announced the appointment of Daniel Goldberger as Chief Executive Officer.

The appointment follows the June 12, 2017 announcement that the Company's CompuFlo® Epidural Computer Controlled Anesthesia System received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Mr. Goldberger's responsibilities will include transitioning Milestone to a commercially focused global medical device company, and formally launching the CompuFlo® Epidural System, which provides anesthesiologists and other health care providers for the first time, the ability to quantitatively determine and document the pressure at the needle tip in real-time.

Epidurals represent a multi-billion dollar global market and potential complications with conventional standard of care include wet tap (punctured dura), neurological injuries, and paraplegia. The CompuFlo® Epidural's proprietary DPS Dynamic Pressure Sensing Technology™ (DPS) allows the CompuFlo® Epidural system to provide objective visual and audible in-tissue pressure feedback that allows anesthesiologists to identify the epidural space.

Mr. Goldberger is a seasoned senior executive, consultant and board member with 35 years of life sciences and medical device experience, including sales, commercial scaling, supply chain, and business analytics. Mr. Goldberger has held senior leadership and board of directors positions at medical technology companies including Xtant Medical Holdings, Sound Surgical Technologies/Solta Medical, Xcorporeal, and Glucon. As CEO of Xtant, he oversaw a tripling of sales from \$30 million to \$90 million over a three and one-half year period. He also guided Xtant through a period of improved profitability and substantially increased enterprise value. With Sound Surgical, he boosted revenue from \$9 million to \$40 million over six years through a strategic restructuring and new product development. Dan holds a BS in Mechanical Engineering from MIT and an MS in Mechanical Engineering from Stanford University.

"I am thrilled to accept this position at such an important inflection point as Milestone transitions from an R&D focused organization to a commercially focused medical device company," said Mr. Goldberger. "Milestone's painless and precise computerized injection technology platform has the potential to transform drug delivery. Over the coming years, we will be laser focused on sales and marketing activities, including building our global distribution network. Since receiving marketing clearance for the first

instruments in Europe, Milestone has been successful in attracting key opinion leaders. Following our recent FDA marketing clearance of the epidural instrument, I look forward to now converting the growing enthusiasm among medical practitioners into broad global commercial adoption.”

Leonard Osser, founder and former Chief Executive Officer and member of the Board of Directors, stated, "We are pleased to announce the appointment of Daniel Goldberger as Chief Executive Officer. He brings a proven track record driving sales and global market adoption of medical devices to Milestone. Dan’s skill sets will be invaluable as we enter the next phase of our growth, in which we will be heavily focused on the commercial rollout of our epidural instrument.”

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete. The Company was granted the FDA marketing clearance of the epidural instrument in U.S. and is currently pursuing regulatory approval for intra-articular instrumenty in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, successfully commercialize its medical devices, achieve expected revenues, and obtain incremental regulatory approvals and otherwise achieve future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

#